MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA – Get Free Report) Director Ramiro Guerrero acquired 11,899 shares of MAIA Biotechnology stock in a transaction that occurred on Thursday, August 20th. The shares were purchased at an average price of $1.37 per share, with a total value of $16,301.63. Following the transaction, the director owned 600,117 shares of the company’s stock, valued at $822,160.29. The trade was a 2.02% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
MAIA Biotechnology Stock Down 2.9%
Shares of MAIA Biotechnology stock traded down $0.04 during trading hours on Monday, reaching $1.35. 227,366 shares of the stock traded hands, compared to its average volume of 804,487. MAIA Biotechnology, Inc. has a one year low of $0.87 and a one year high of $3.19. The firm has a market capitalization of $82.12 million, a price-to-earnings ratio of -2.18 and a beta of 0.24. The company has a 50 day moving average price of $1.37 and a 200 day moving average price of $1.46.
MAIA Biotechnology (NYSEAMERICAN:MAIA – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Sell-side analysts anticipate that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current year.
Institutional Trading of MAIA Biotechnology
About MAIA Biotechnology
MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.
The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.
Featured Articles
- Five stocks we like better than MAIA Biotechnology
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for MAIA Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAIA Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
